RxDoctor Payments DataLook up a doctor →

Lucius Blanchard, MD

MOHS-Micrographic Surgery · Las Vegas, NVNPI 1134147853

Payments from drug & device makers

$14,094in general payments, 2019–2025

Across 939 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Amgen$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Sanofi$1K
  • Regeneron Healthcare Solutions, Inc.$772
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$13,76398%
  • Education$3312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few mohs-micrographic surgery providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,066,242
Medicare patients
1,987
Services billed
9,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab14$123,185
OtezlaApremilast12$53,736
Dupixent SyringeDupilumab12$52,955
Clobetasol Propionate209$8,283
Ketoconazole584$8,037
Triamcinolone Acetonide503$7,945
Doxycycline Monohydrate278$6,688
Mometasone Furoate287$4,430
Fluorouracil58$4,127
Clindamycin Phosphate124$3,921
Cephalexin511$2,830
Metronidazole34$2,563
Hydrocortisone181$1,926
Hydroxyzine Hcl117$1,920
Imiquimod29$863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,139$53,73612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few mohs-micrographic surgery providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other mohs-micrographic surgery in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →